Regular Companies:
|
4D Pharma PLC - [LON:DDDD]4D pharma plc is a clinical-stage pharmaceutical company and a world-leader in the development of live biotherapeutics – a new class of medicines derived from the human microbiome. Leveraging its MicroRx discovery platform, the company has 15 programs in development, spanning diverse therapeutic areas including GI, autoimmune, oncology, respiratory and CNS. 4D’s lead program – Blautix – is a live biotherapeutic for the treatment of irritable bowel syndrome (IBS), which recently completed a successful Phase I study in IBS patients.
http://www.4dpharmaplc.com/ |
|
Accera, Inc.Accera is a clinical stage biotechnology company that develops therapies for central nervous system disorders. Accera’s proprietary scientific platform addresses numerous unmet needs in brain health including Alzheimer’s disease. We believe our development-stage proprietary compounds have innovative mechanisms of action that have the potential to positively impact patients’ lives as well as those of their families. Our executive management team includes globally recognized specialists in central nervous system diseases who together leverage the latest scientific knowledge and understanding of neurological disorders.
http://www.accerapharma.com/ |
|
AcelRx Pharmaceuticals, Inc. - [NASDAQ:ACRX]AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain in medically supervised settings. The Company’s two late-stage product candidates, ARX-04 and Zalviso™, were developed using our non-invasive, sublingual formulation technology that delivers sufentanil, a strong opioid analgesic.
http://www.acelrx.com/ |
|
Acticor Biotech SASActicor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes.
http://acticor-biotech.com/ |
|
Addex Therapeutics Ltd.Addex Therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G-Protein Coupled Receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine receptors, such as the TNF receptor superfamily. Many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery.
http://www.addextherapeutics.com/ |
|
Allecra Therapeutics GmbHAllecra is a clinical stage biopharmaceutical company established in 2013 in the European BioValley Life Sciences region located in the Upper Rhein valley and encompassing northwest Switzerland, southwestern Germany and the Alsace Region of France. Allecra is focused on the development of novel treatments to combat multi drug-resistant bacterial infections. The company is based on a strategic partnership between its Founders, Orchid Chemicals and Pharmaceuticals Ltd. (Chennai, India) and its lead investors Forbion Capital Partners and Edmond de Rothschild Investment Partners. Allecra’s mission is to contribute towards the global effort to combat antibiotic resistance by developing new treatments which overcome emerging resistance mechanisms thereby saving lives of patients whose infections may otherwise may be inadequately treated.
http://www.allecra.com/ |
|
Anagenesis BiotechnologiesAnagenesis Biotechnologies is a preclinical‐stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. Anagenesis Biotechnologies secured two private investments from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area and from Cap Innov'Est. Anagenesis Biotechnologies aim is to become the world leader in muscle-related diseases.
http://anagenesis-biotech.com/ |
|
Apogenix AGApogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target differentTNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.
http://apogenix.com/ |
|
Arsanis, Inc.Arsanis is leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and post-infection treatment of serious infectious diseases. Our current programs address specific pathogens and pathogenic processes selectively rather than aiming to broadly eliminate bacteria, potentially allowing Arsanis to address critical infections without contributing to the problem of antibiotic resistance.
http://www.arsanis.com/ |
|
Atlantic Healthcare PLCAtlantic Healthcare plc is an international specialty pharmaceutical company. We focus on the development and commercialisation of products that address niche unmet needs. These products are intended for patients under the management of physicians in the hospital and specialist care sector which is showing one of the highest growth rates in the pharmaceutical industry. We are building a portfolio of products that address needs in clearly defined patient groups. These target groups’ needs are either poorly served or have no approved treatment. Our portfolio contains products that have unique positioning characteristics, intellectual property protection and market exclusivity. Key medical opinion leaders have confirmed they will consider these products for their patients once approved. This provides Atlantic Healthcare with the potential to be a high growth profitable company.
http://www.atlantichc.com/ |
|
Aurealis Pharma AGIn Aurealis Pharma we are dedicated to advancing science and health; develop an effective, safe and economical treatment method that greatly improves the quality of life for chronic inflammation and cancer sufferers. Thanks to advancements in modern biotechnology and our research and development in cell-based therapies we have developed a proprietary technology, which utilizes genetically modulated probiotics that deliver a variety of therapeutic proteins to diseased tissue, thus modulating local immune system and enabling healing. A life-changing breakthrough that offers severe and chronic inflammation and cancer sufferers a much-improved, safer, and more cost-effective treatment option.
http://www.aurealispharma.com/ |
|
Avexxin ASAvexxin AS is a clinical stage pharmaceutical company focused on developing novel first in class small molecules for patients suffering from various inflammatory conditions. Current pipeline includes compounds against psoriasis and other dermatological disorders, rheumatoid arthritis and glomerulonephritis. Avexxin’s advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of chronic inflammatory disorders. Compounds have also been successfully tested in various cancer models. The NCE’s specifically target the group IVa cPLA2 enzyme regulating the cytokine-induced activation of the pro-inflammatory transcription factor NF-κB.
http://avexxin.com/ |
|
BiophytisBiophytis is a biotechnology company created in 2006 as a spin-off of Université Pierre et Marie Curie (Paris). It develops first-in-class drugs to treat degenerative illnesses associated with aging for which there is curently no treatment. Biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (BIO101, BIO103) and dry age-related macular degeneration (BIO201).
http://www.biophytis.com/ |
|
Biosceptre International Ltd.Biosceptre International is a private, unlisted biotechnology company based in Cambridge, United Kingdom that is developing and commercializing antibody technologies to address a wide range of applications in the diagnosis and treatment of cancer. Biosceptre’s technology is centered on P2X7, specifically nf-P2X7, a form of the receptor in which a critical function, the formation of a large transmembrane pore on prolonged activation, has been lost. This loss in function is important in mediating key aspects of the receptors involvement in the transition of cells to a cancerous state.
http://www.biosceptre.com/ |
|
Cantargia AB - [CANTA:ST]Cantargia is developing an antibody against the IL1RAP target molecule for cancer treatment. Preclinical data indicate that the antibody has the potential to be used for treatment of several forms of cancer. Cantargia will be focusing the initial development activities on non-small cell lung cancer (NSCLC) and pancreatic cancer. A product candidate CAN04 has been selected and a clinical phase I/IIa study in these cancers will be initiated in late 2016. The goal is to develop a new treatment for future cancer therapies.
http://cantargia.com/ |
|
Cellestia Biotech AGCellestia Biotech is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Our anti-cancer CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.
http://www.cellestiabiotech.com/ |
|
Celyad S.A. - [CYAD:BB]Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products.
http://www.celyad.com/ |
|
Clayton Biotechnologies, Inc.Clayton Biotechnologies, Inc. is a for-profit company which facilitates the commercialization of medical discoveries made by the Clayton Foundation for Research and its supporting entities. We have over 100 granted patents and numerous published and unpublished pending patent applications.
http://www.claytonbiotech.com/ |
|
CorMedix, Inc. - [NYSEMKT:CRMD]CorMedix Inc. is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product in Europe isNeutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients, and patients receiving total parenteral nutrition, IV hydration and/or IV medications. Infection and thrombosis represent key complications among patients with central venous catheters. These complications can lead to treatment delays and increased costs to the healthcare system when they occur due to hospitalizations, need for IV antibiotic treatment, long-term anticoagulation therapy, removal / replacement of central venous catheter, related treatment costs and increased mortality when they occur.
http://www.cormedix.com/ |
|
DiaMedica Inc.DiaMedica is a biopharmaceutical company focused on developing innovative treatments for neurological and kidney diseases where no current therapies are available. DiaMedica's common shares are listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
http://www.diamedica.com/ |
|
Double Bond Pharmaceutical AB - [DBPB:SS]Double Bond Pharmaceutical is a fast growing pharmaceutical company which develops and commercializes innovative first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders. The main aim of the company is to provide patients and the market with more efficient and safe products especially in areas where these needs are unmet.
http://www.doublebp.com/ |
|
Evaxion BiotechEvaxion Biotech is pioneering in silico discovery and the development of prophylactic vaccines and therapeutic antibodies. Based on our new ground-breaking in silico vaccine antigen discovery platform EDEN, Evaxion is able to identify novel antigens that elicit a highly cross-protective immune response, thereby overcoming the limitations of state-of-the-art vaccine discovery technologies. EDEN integrates big data, artificial intelligence and supercomputing in one platform, thereby enabling rapid and accurate discovery of novel antigens in any bacterial pathogen. EDEN targets evasion strategies evolved over thousands of years by bacteria enabling Evaxion to defeat serious bacterial infections by bringing novel highly effective vaccines and antibodies to patients.
http://www.evaxion-biotech.com/ |
|
Galena Biopharma, Inc. - [NASDAQ:GALE]Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
https://galenabiopharma.com/ |
|
GamaMabs Pharma SAGamaMabs Pharma develops innovative monoclonal antibodies in cancer. GamaMabs’ lead project is the monoclonal antibody (mAb) GM102 which targets Anti-Müllerian Human Receptor II (AMHRII), an unaddressed specific target in ovarian cancer. The company has rights on a glyco-engineering technology (EMABling®) developed at LFB (France) which enhances the efficacy of mAbs through the activation of immune cells. The main objective of GamaMabs is to develop its pipeline up to Proof of Concept in patients.
http://www.gamamabs.com/ |
|
GeNeuro SA - [GNRO:FP]GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). GeNeuro is developing a new approach for the treatment of MS by seeking to block a suspected source of the inflammatory and neurodegenerative components of the disease, rather than targeting the immune response of the body as do most current treatments.
http://www.geneuro.ch/ |
|
Heptares TherapeuticsHeptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.
http://www.heptares.com/ |
|
MDxHealth - [MDXH:BB]MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.
http://mdxhealth.com/ |
|
MOLOGEN AG - [MGN:GR]MOLOGEN AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. Our most important developments to date are the DNA immunomodulator MGN1703, which we are currently subjecting to clinical trials in the treatment of colorectal cancer and small-cell lung cancer. Furthermore our cell-based cancer therapy MGN1601 for the treatment of renal cancer, which is also a highly promising product, is currently undergoing clinical development as well.
http://www.mologen.com/ |
|
Novogen Limited - [ASX:NRT]Novogen is an oncology-focused, Australian-US drug development company, traded on both the Australian Securities Exchange (NRT) and on NASDAQ (NVGN). Novogen has two proprietary drug discovery platforms, the superbenzopyrans (SBPs) and the anti-tropomyosins (ATMs), which have provided first-in-class agents with potential application across a range of oncology indications. The Company has three lead molecules Cantrixil, Anisina, and Trilexium, which are in advanced preclinical development for various cancer types.
http://www.novogen.com/ |
|
Onconova TherapeuticsOnconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells.
http://www.onconova.com/ |
|
PIQUR Therapeutics AGPIQUR’s vision is to improve the lives of cancer patients with breakthrough medicines. Despite significant advances in the cancer therapies, there remains a high unmet medical need for therapies that not only prolong patients’ survival but also significantly improve quality of life. PIQUR was founded in August 2011 by Vladimir Cmiljanovic, Bernd Giese, Matthias Wymann, Andreas Emmenegger and Ralf Rosenow as a spin-off of the University of Basel. The company focuses on the discovery and development of innovative anti-cancer drugs based on the inhibition of the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) pathways, one of the most promising research areas in oncology and clinically validated drug targets. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial.
http://www.piqur.com/ |
|
Prexton TherapeuticsRecently founded in Geneva, Switzerland, Prexton Therapeutics is developing novel mGluR4 PAM series, which were originally developed by Merck Serono, an affiliate of Merck KGaA in Darmstadt, Germany. Considerable effort has gone into creating chemical diversity of drug-like molecules with properties suitable for brain diseases, such as blood-brain barrier penetration or an ADME/PK profile optimized to achieve target coverage. The compounds show high potency on the mGluR4 target and selectivity over the other mGluR subtypes. We believe that these compounds represent a unique opportunity to build a high quality development pipeline of therapeutics for Parkinson’s disease.
http://www.prextontherapeutics.com/ |
|
Provecs Medical GmbHProvecs Medical GmbH, a biopharmaceutical company, develops immunotherapies for cancer. Its product includes Immunalon for treatment of infectious diseases and vaccinations. At Provecs we are convinced that controlling the tumor cell neighborhood enables therapy of cancer. Our therapeutics deliver all signals necessary to make the immune system respond and cancer patients survive.
http://www.provecs.com/ |
|
Provectus Biopharmaceuticals, Inc. - [NYSEMKT:PVCT]Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.
https://www.pvct.com/ |
|
RXi Pharmaceuticals, Inc. - [NASDAQ:RXII]RXi Pharmaceuticals Corporation is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs. Building on the pioneering work of RXi's Scientific Advisory Board Chairman and Nobel Laureate Dr. Craig Mello, our discovery and clinical development programs are based on our proprietary RNAi (sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
http://www.rxipharma.com/ |
|
Sensorion SA - [EPA:ALSEN]Sensorion is a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease. Sensorion develops innovative therapies dedicated to the treatment of vestibular and cochlear pathologies. Our scientists are focused on : relieving acute symptoms such as vertigo and tinnitus, reducing impairments (loss of balance, hearing loss ...) related to permanent damage of the inner ear, restore, to the extent possible, the functions already impacted.
http://www.sensorion-pharma.com |
|
Strekin AGStrekin AG is a start-up Life Sciences Company headquartered in Basel, Switzerland. Strekin AG focuses on discovering the untapped therapeutic potential in existing molecules to transform the lives of patients with diseases of cell stress-related inflammatory pathways.
http://www.strekin.com/ |
|
Synaffix BVFormed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.
http://www.synaffix.com/ |
|
Synpromics Ltd.Synpromics is developing a strategic portfolio of valuable synthetic promoters for specific application across its target markets, such as cell & gene therapy, bio-manufacturing and industrial & agricultural biotechnologies. Synpromics was founded in 2010 to commercialise proprietary and patent-pending technology, developed by Dr Michael L Roberts, in the emerging field of synthetic biology. This is a highly disruptive technology putting the power to control gene expression in almost any condition of interest into the hands of scientists developing next generation technologies, therapeutics and diagnostics.
http://www.synpromics.com/ |
|
Tonix Pharmaceuticals Holding Corp.Tonix is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD). These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix's lead product candidate, TNX-102 SL, is a sublingual tablet containing low-dose cyclobenzaprine HCl and is designed for daily use at bedtime for the management of fibromyalgia.
http://www.tonixpharma.com/ |
Emerging Companies:
|
3Brain GmbH3Brain is the world's first company that sells large scale high resolution MEA recording platforms and CMOS-MEA biochips. 3Brain's patented core technology spans the field of large scale high resolution microelectrode array systems for in-vitro electrophysiology. Our key competences are focused on CMOS integrated bio-sensor arrays for recording extracellular signals from electrogenic cells, networks and tissues, such as in-vitro neuronal networks, brain slices and cardiac tissue preparations.
http://www.3brain.com/ |
|
Anima Biotech Ltd.Anima Biotech developed a novel platform for the discovery of drugs that control Protein Translation. Our platform gives new hope for treating severe diseases with hard or undruggable targets, where existing methods have failed for many decades.
Our new approach is enabled by a breakthrough, patented technology. Anima's Protein Synthesis Monitoring (PSM) technology enables for the first time the visualization and monitoring of protein synthesis by ribosomes in living cells in real time. Our Translation Control Therapeutics platform uses this information together with specialized high content screening methods to discover molecules that regulate this process, correcting problems in over-expression or under-expression of target proteins. The platform is the result of over a decade of development in collaboration with a broad network of 15 leading academia and research institutions that have validated and expanded the scope and reach of our technology. Anima's drug discovery pipeline is currently focused on three outstanding therapeutic areas where the underlying cause of the disease is closely linked to protein translation: Fibrosis (regulation of Collagen type I synthesis), Viral Infections (modulation of host mechanisms involved in virus replication) and Autism (regulation of protein synthesis in Synapses.) Protein translation is a major biological process and the ability to control it opens a new therapeutic strategy for many additional diseases. We seek to maximize the therapeutic potential of our platform by partnering with pharma companies in their drug discovery programs. http://www.animabiotech.com/ |
|
ATRIVA Therapeutics GmbHATRIVA focuses on repurposing existing so-called MEK-inhibitors, originally used in oncology, which are already marketed or have undergone clinical investigations. ATRIVA scientists are leading experts for influenza viruses. They found that virus replication is dependent on a specific cellular pathway, which can be effectively blocked by MEK-inhibitors.
http://atriva-therapeutics.com/ |
|
Biologics Resources LLC is a privately owned biologics company. It was created in 2011 by Dr. Lallan Giri who has had successful career in biodefense biologics, pediatric vaccines, and biologic therapeutics (antibodies) with multi-national pharmaceutical companies such as Wellcome - Pharmaceuticals, Sanofi Pasteur, Glaxo Wellcome, and Emergent Biosolutions, Inc. Dr. Giri’s expertise are in the areas of vaccine and therapeutics development.Biologics Resources was founded in 2011, in Germantown, Maryland with Dr. Giri’s personal investment of $ 2 Millions to develop a conjugate anthrax vaccine by licensing the technology from N.I.H. In 2012, Biologics Resources was awarded a grant of approximately $5 million for 5 years from N.I.H. to develop a conjugate anthrax vaccine.
http://www.biologicsresources.com/ |
|
CellProthera SASCellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF). CellProthera is in clinical phase, currently conducting an international clinical trial phase I/IIB including 44 European patients and about to start a supplementary trial in Singapore. Next will follow a phase III in both Europe and North America.
http://www.cellprothera.com/ |
|
Edinburgh Molecular Imaging Ltd.Edinburgh Molecular Imaging is an Edinburgh BioQuarter spin-out company from the University of Edinburgh, developing an Optical Molecular Imaging technology that can help diagnose and monitor of several major diseases. The company’s innovative technology revolves around the development of fluorescent imaging reagents that detect harmful processes deep inside the human body, at the bedside, in real time and at molecular resolution. The company is initially focusing on lung conditions, but the technology is applicable to a wide range of diseases.
http://www.edinimage.com/ |
|
Eos Biosciences, Inc.Eos Biosciences Inc. is a privately held Los Angeles-based Nanomedicines company founded in 2013. The Company has secured an exclusive world-wide license to a novel and innovative drug-targeting platform technology developed by Dr. Lali Medina-Kauwe at Cedars-Sinai Medical Center (Los Angeles). The technology is based on generating self-assembling, nanobiologic particles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload.
http://eosbiosciences.com/ |
|
eTheRNA immunotherapies NVeTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
http://www.etherna.be/ |
|
Ex Scientia Ltd.Ex Scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. This is achieved by either dialling-in extra desired targets to improve phenotypic response or removing unwanted off-targets to improve safety. We focus on exploiting our advanced design technologies to the development of compounds with tailored pharmacology and in particular a portfolio of bispecific drugs that tackle unmet medical need.
http://www.exscientia.co.uk/ |
|
F2G Ltd.F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline.
http://www.f2g.com/ |
|
GREENBONE ORTHO SRLGreenBone Ortho srl is a start up founded in 2014 and located in Faenza (Italy). GreenBone is developing a highly innovative, bone regenerating, load-bearing implants to treat severe fractures and conditions such as trauma and tumours that result in extensive bone loss. The company’s patented technology transforms Bamboo into an established, widely used biomaterial, hydroxyapatite, to provide a bone graft scaffold with unique and never achieved so far mechanical strength, weight bearing and bone regeneration properties needed for large implants. New functional bone formation with GreenBone has been demonstrated in vitro and in vivo. GreenBone will begin human studies early 2017 in patients with non-healing (non-union) critical size fractures. The company is led by a world class team that has advanced multiple orthopaedic products from bench-to-market.
http://greenbone.it/ |
|
ILTOO PharmaILTOO Pharma a clinical stage biotech company developing biotherapies for the treatment of autoimmune diseases and inflammatory disorders. ILTOO Pharma’s main activity is the repositioning of human recombinant interleukin 2 (rhIL2) following a breakthrough discovery related to its mode of action and its applications at low dose. The drug based on this discovery and developed by ILTOO Pharma is named ILT-101.
http://www.iltoopharma.fr/ |
|
ImCyse
Imcyse is pioneering the development of a new class of specific immunotherapeutic vaccines. Our new technology platform is based on the discovery of synthetic peptide vaccines to block the immune processes causing immune-mediated diseases. Imcyse therapeutic vaccines therefore offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
http://www.imcyse.com/en |
|
ImmunoMet Therapeutics, Inc.ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. With our devotion to research and development, we aim to bring multiple metabolic regulators that can be combined with and enhance the current standard-of-care or new therapies to control cancer recurrence.
http://immunomet.com/ |
|
Inflamalps SA
Inflamalps is a biopharmaceutical company established in Valais, Switzerland. Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin”. Our focus is on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology.
http://www.inflamalps.com/ |
|
IO Biotech ApSIO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
http://www.iobiotech.com/ |
|
Lytix Biopharma ASLytix Biopharma’s technology is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to end Phase II, and then collaborate with partners for the final stages of product development and commercialization.
http://www.lytixbiopharma.com/ |
|
Medesis Pharma SAMedesis Pharma SA, a clinical stage pharmaceutical company, develops new treatments based upon a unique nanotechnology allowing administration of pharmacologically active metals and the extraction of toxic metals. Medesis Pharms has developed Aonys®, a safe, GMP manufactured nanotechnology which allows non-invasive, systemic delivery of water soluble active ingredients with a highly efficient mechanism of cellular entry. The technology is currently developed for the delivery of metal ions or chelates as new therapies for diseases with high unmet medical need.
http://www.medesispharma.com/ |
|
Mymetics - [OTCMKTS:MYMX]Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of 5 vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Astellas Pharma, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB.
http://www.mymetics.com/ |
|
Nouscom AGNouscom AG develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
http://www.nouscom.com/ |
|
Novigenix SANovigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.
https://www.novigenix.com/ |
|
Novitrhera SASFounded with the mission to exploit kinases for the development of small-molecule cancer immunotherapeutics.
http://novithera.com/ |
|
Pantarhei OncologyPantarhei Oncology (PRO) is focusing on reproductive tract related cancer including breast and prostate cancer. It aims to develop new treatment concepts until and including proof-of-concept in the human (phase 2). Thereafter the products are licensed out for final phase 3 development and sales and marketing to big pharma companies.
http://www.pantarheibio.com/ |
|
PeptiMimesisPeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors. PeptiMimesis will develop its pipeline against key targets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.
http://www.peptimimesis.com/ |
|
Pharmasum Therapeutics ASPharmasum Therapeutics is a private, Norwegian pharmaceutical company focused on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The Company shall develop drugs to at least Proof-of-Concept stage, but will be seeking strategic partnerships with larger pharmaceutical companies potentially for early-stage collaborations, late-stage development and marketing.
http://www.pharmasum.com/ |
|
ProAxsis Ltd.ProAxsis, is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. Our rapid and easy-to-use tests incorporate patented “ProteaseTags®”; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as cystic fibrosis and COPD.
http://proaxsis.com/ |
|
RDD PharmaRDD Pharma is a specialty drug company, developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.The company utilizes a high-reward, low-risk business model by re purposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.
http://www.rddpharma.com/ |
|
SelonterraSelonterra develops therapies for Alzheimer's disease and Parkinson’s disease based on our breakthrough, novel mechanisms on genetics and gene regulatory networks. We integrate human genetics, molecular pathway analyses and gene regulation to identify disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics.
http://www.selonterra.com/ |
|
TM3 Therapeutics LLCTM3 Therapeutics is a company that developed proprietary technology to create fully inactivated, whole agent vaccines, patented platform technology for the development of therapeutic vaccines against cancers and a novel method for in vitro generation of fully human monoclonal antibodies against virtually unlimited antigens.
http://www.tm3therapeutics.com/ |
|
Triskel Biopharmaceuticals AGTriskel Biopharmaceuticals AG, headquartered in Basel, Switzerland is specialised in the development of late stage and clearly differentiated biotechnology drugs, with a focus on the very sizeable speciality hospital pediatric market. The lead compound in development by Triskel Bio is TB 101, an innate recombinant-human enzyme, identified by the company as serving an underserved therapeutic area of high unmet medical need, namely in preventing and reducing long-term chronic respiratory morbidity (CRM) in the population of prematurely born neonatal patients. Other clinical indications for TB 101 are also subsequently envisaged.
http://www.triskelbio.com/ |
Israel Biomed Panel: Elevator Session
|
BioShaiBioShai focuses on commercializing PDx™, the first blood test for diagnosing Parkinson’s disease (PD). PDx™ increases diagnostic certainty at an early stage, without needing to wait for disease progression, and is expected to significantly improve the development of novel PD drugs, by reducing False-Positive enrolment to clinical trials.
http://www.youdim.com/portfolio/ |
|
CurewizeCurewize specializes in lab tests that measure microRNA, which controls genes involved in cancer. Its lead product is ProALL™, a predictive assay for the therapeutic management of Acute Lymphoblastic Leukemia (ALL). The company is proceeding with the development of exciting new R&D findings on microRNA biomarkers, enabling personalized treatment of a large number of solid cancers, jointly with Schneider Hospital Oncology department.
http://www.youdim.com/portfolio/ |
|
N2B N2B’s is a pharmaceutical company developing medical care for early Parkinson’s disease (PD) patients suffering from depression through the proprietary reformulation of existing drugs. Its lead product is a drug-device combination of dry powder Rasagiline which is administered via an intranasal device. N2B is supported in Israel by the Office of the Chief Scientist (OCS) and its new executive arm, the Authority for Technological Innovation (ATI).
http://www.youdim.com/portfolio/ |
|
Omnix Medical Ltd.Omnix Medical's novel technology is based on genetically engineered antimicrobial peptides which physically damage the bacterial membrane with no toxic effect to eukaryotic cells. These peptides are highly potent against resistant bacteria and are soluble, stable and safe. Currently, the company focuses on ESKAPE Gram-negative drug resistant pathogens bacteria such as: K. pneumoniae spp, A. baumannii, P. aeruginosa and Enterobacter spp.
www.omnixmedical.com |
|
Saturix Ltd.Suturing is one of the most complex, time consuming & risk related procedures, involved in laparoscopic surgeries. "Saturix" is an Israeli medical device start-up company which developed the "Persew", the next generation solution for laparoscopic suturing. The "Persew" is a novel, semi-automatic, simple to maneuver anchor based suturing device, which shortens and simplifies the laparoscopic suturing process tremendously, changing the whole paradigm of laparoscopic surgical suturing.
http://www.saturix-surgical.com/ |
|
Synvaccine Ltd.SynVaccine, applies viral computer aided design (CAD) and computer aided manufacturing (CAM) technology to rapidly and cost effectively design safe, highly-effective, tailor-made oncolytic-viruses and attenuated virus vaccines. Since this technology can be applied to any virus, it has a multitude of applications and can generate highly differentiated products in oncology (highly accurate immune-oncolytic viruses), infectious disease (such as ZIKA and dengue), and animal health (veterinary vaccines such as PCV2).
www.synvaccine.com |
|
TPCeraTPcera ltd. develops a new type of immunomodulatory compounds that shifts the immune system from its inflammatory state into its anti-inflammatory state. The company is focused on shifting macrophages from M1 to M2 and by that to modulate autoimmune diseases. TPC1022 is the company lead compound - Subcutaneous & oral administration have been tested so far in pre-clinical studies on three autoimmune mice models – Lupus, Colitis & Rheumatoid Arthritis, with promising results.
http://vlx.co.il/project/tpcera/ |
|
Z.M.D Medical LtdZ.M.D develops and commercializes a revolutionary therapeutic remedy to cure cancer of all types using the immune system. The core technology is based on specific bacteria strains, which are located in the natural microflora in the colon of a healthy individual. Z.M.D has developed a therapeutic remedy (capsule) to cure cancer that is formed from bacteria, which are taken from a healthy individual with high synthetization activity.
http://www.zmdgroup.com/ |